C

Compass Therapeutics, Inc. (CMPX)

NCM – Real Time Price. Currency in USD

2.20

+0.01 (0.23%)

Market open: Aug 12, 2026, 10:06 AM EDT

2.21

+0.01 (0.45%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Compass Therapeutics, Inc. (CMPX)

NCM – Real Time Price. Currency in USD

2.20

+0.01 (0.23%)

Market open: Aug 12, 2026, 10:06 AM EDT

2.21

+0.01 (0.45%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

06.08.2026

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

The Company expects feedback from the FDA this quarter regarding the COMPANION-002 Phase 2/3 data for tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), prior to a potential BLA filing later this year. Tovecimig data from this study has also been selected for an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress in October.

Videos

No Data

There is no data to display

Press releases

06.08.2026

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

The Company expects feedback from the FDA this quarter regarding the COMPANION-002 Phase 2/3 data for tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), prior to a potential BLA filing later this year. Tovecimig data from this study has also been selected for an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress in October.

Search stocks

Compass Therapeutics, Inc. (CMPX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Compass Therapeutics, Inc. (CMPX)

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

Videos

No Data

Press releases

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update